A pilot study of recombinant insulin-like growth factor-1 in seven multiple sclerosis patients
Explore this paper's citation graph
Summary
Although rhIGF-1 did not alter the course of disease in this small cohort of MS patients, the drug was well tolerated and further studies using rhIGFs alone or in combination with other therapies may be of value because of the proposed mechanism of action of this growth factor on the oligodendrocyte and remyelination.
- Type
- article
- Published
- 2002-02-01
- Cited by
- 94
- References
- 32
- OpenAlex
- https://openalex.org/W1988358907
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:19932690
Keywords
Medicine, Multiple sclerosis, Magnetic resonance imaging, Remyelination, Adverse effect
References
- Growth hormone and prostate cancer: guilty by association?
- Insulin-like growth factor I treatment reduces clinical deficits and lesion severity in acute demyelinating experimental autoimmune encephalomyelitis
- Chronic Relapsing Experimental Autoimmune Encephalomyelitis: Effects of Insulin‐like Growth Factor‐I Treatment on Clinical Deficits, Lesion Severity, Glial Responses, and Blood Brain Barrier Defects
- Growth factors and myelin regeneration in multiple sclerosis
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis
- Insulin-like growth factor I treatment reduces demyelination and up-regulates gene expression of myelin-related proteins in experimental autoimmune encephalomyelitis.
- Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group.
- Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.
- Regulation of Oligodendrocyte Development and CNS Myelination by Growth Factors: Prospects for Therapy of Demyelinating Disease
- Amyotrophic lateral sclerosis and vitamin E
- Correspondence of closest gradient Voxels—A robust registration algorithm
- Method for quantification of brain, ventricular, and subarachnoid CSF volumes from MR images.
- Distinct Patterns of Multiple Sclerosis Pathology Indicates Heterogeneity in Pathogenesis
- Regulation of experimental autoimmune encephalomyelitis with insulin-like growth factor (IGF-1) and IGF-1/IGF-binding protein-3 complex (IGF-1/IGFBP3).
- Using gadolinium‐enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis
- TSH-secreting pituitary macroadenoma: Rapid tumor shrinkage and recovery from hyperthyroidism with octreotide
- Effect of interferon beta-1b in MS: assessment of annual accumulation of PD/T2 activity on MRI. UBC MS/MRI Analysis Group and the MS Study Group.
- Insulin-like growth factor-I given subcutaneously reduces clinical deficits, decreases lesion severity and upregulates synthesis of myelin proteins in experimental autoimmune encephalomyelitis.
- A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group.
- A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases.
Cited by
- Relationship between inflammatory lesions and cerebral atrophy in multiple sclerosis
- Remyelination strategies: New advancements toward a regenerative treatment in multiple sclerosis
- Stepchild or Prodigy? Neuroprotection in Multiple Sclerosis (MS) Research
- The Role of Insulin-Like Growth Factors and Insulin-Like Growth Factor–Binding Proteins in the Nervous System
- The insulin-like growth factor system in multiple sclerosis.
- Targeting Insulin-Like Growth Factor-1 Signaling into the Central Nervous System for Promoting Myelin Repair
- Therapeutic Approaches to Multiple Sclerosis
- Remyelination in multiple sclerosis: a new role for neurotrophins?
- Developing therapeutics for the treatment of multiple sclerosis
- Targeting Insulin-Like Growth Factor 1 Leads to Amelioration of Inflammatory Demyelinating Disease
- Advancement of therapies for neuroprotection in multiple sclerosis
- Circulating insulin-like growth factors and related binding proteins are selectively altered in amyotrophic lateral sclerosis and multiple sclerosis.
- Recombinant human IGF-1 for patients with schizophrenia.
- Mediators of Oligodendrocyte Differentiation During Remyelination
- Imaging of multiple sclerosis: Role in neurotherapeutics
- Remyelinating strategies for the treatment of multiple sclerosis.
- Signaling axis in schwann cell proliferation and differentiation
- Inflammation and Neuroaxonal Injury in Multiple Sclerosis and AIDS Dementia Complex: Implications for Neuroprotective Treatment
- Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta.
- New findings and old controversies in the research of multiple sclerosis and its model experimental autoimmune encephalomyelitis
Related papers
- Altered frequency of T regulatory cells is associated with disability status in relapsing-remitting multiple sclerosis patients.
- A non-randomized clinical trial to evaluate the effect of fingolimod on expanded disability status scale score and number of relapses in relapsing-remitting multiple sclerosis patients
- Expanded disability status scale in Multiple Sclerosis: Relationship to visual evoked potential
- MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS)
- A LONGITUDINAL STUDY OF ABNORMALITIES ON MRI AND DISABILITY FROM MULTIPLE SCLEROSIS
- СРАВНИТЕЛЬНЫЙ АНАЛИЗ ЭФФЕКТИВНОСТИ ТЕРАПИИ ИНТЕРФЕРОНОМ-БЕТА-1B И НАТАЛИЗУМАБОМ У ПАЦИЕНТОВ С РЕМИТИРУЮЩИМ РАССЕЯННЫМ СКЛЕРОЗОМ
- A longitudinal study of abnormalities on MRI and disability from multiple sclerosis.
- Efficacy of interferon β1a (Cinnovex) in relapsing-remitting multiple sclerosis patients
- Assessment of Nutritional Status and Expanded Disability Status Scale in Women with Multiple Sclerosis in Chennai (south India) and the Impact of a Nutrition Education Program